Understanding Continuous Glucose Monitoring: What Actually Happens

A CGM works through a small sensor—roughly the size of a postage stamp—inserted under your skin, typically on your abdomen or arm. The sensor measures interstitial glucose (glucose in the fluid between cells) approximately every 5 to 15 minutes, depending on the device. Think of it like having a tiny weather station embedded in your skin that reports atmospheric conditions every few minutes, rather than checking a thermometer once at noon.

The sensor contains an enzyme—usually glucose oxidase—that reacts with glucose molecules and produces an electrical signal. That signal travels wirelessly to a reader device or your smartphone. The chemistry is elegant but imperfect. Interstitial glucose lags behind blood glucose by roughly 5-15 minutes, which matters when you’re rapidly dropping or spiking. Your body doesn’t actually feel what the sensor reads at that exact moment—you feel what your glucose was doing 10-15 minutes earlier. This lag explains why some patients experience hypoglycemic symptoms before their CGM alerts them.

Most systems store 8-14 days of data and transmit readings every 1-5 minutes. The Dexcom G7 transmits every 5 minutes and stores 12 days. The Freestyle Libre 2 requires you to scan it or uses Bluetooth to send readings every minute. Medtronic’s Guardian 4 integrates directly with insulin pumps and communicates every 5 minutes. This constant stream of data is what separates CGMs from traditional finger-stick testing—it’s surveillance of your glucose patterns, not snapshots.

Key Facts About CGM Technology

Why Glucose Monitoring Matters: The Causes and Risk Factors Discussion

You might think this section should explain “causes of needing a CGM,” but that misses the deeper question: why do some diabetics struggle with glucose control while others don’t, even on identical regimens?

The obvious factors exist—insulin resistance severity, beta cell function, medication adherence. But here’s what most websites skip: circadian insulin sensitivity varies dramatically between individuals. Your body’s insulin sensitivity isn’t consistent across the 24-hour cycle. Some patients are profoundly insulin-resistant at dawn (dawn phenomenon), while others spike unpredictably after lunch. CGMs reveal these patterns; finger sticks never can. A patient checking glucose at 7am and 12pm will completely miss the 10am spike that happens daily.

Stress hormones—cortisol, adrenaline—create glucose swings that aren’t food-related. Menstrual cycle phases affect insulin sensitivity in women, with progesterone increasing requirements by up to 30% in some individuals. Sleep deprivation worsens insulin sensitivity within a single night. None of these factors announce themselves on a single blood glucose reading. They’re only visible as patterns across days of continuous data.

The less-discussed risk factor: glucagon dysregulation. Some patients with Type 2 diabetes have impaired glucagon suppression—their liver keeps pumping glucose out even when blood glucose is already elevated. Others have blunted glucagon response to hypoglycemia, meaning they don’t produce enough glucagon when they drop low. CGMs can hint at these patterns (persistently elevated fasting glucose despite no food intake, or failure to recover quickly from lows), but diagnosis requires specific testing.

What Patients Actually Experience: Daily Signs and Symptoms

The biggest misconception about CGM symptoms: patients think they’re monitoring themselves for symptoms. Actually, CGMs create awareness of asymptomatic patterns.

Most diabetics experience erratic energy levels—crushing fatigue at 3pm, hyperalert at 9pm—without understanding these correlate to glucose swings. A CGM reveals that 3pm crash happens every day when glucose drops from 180 to 110 in 30 minutes. That afternoon anxiety? It’s a 90-minute glucose spike after your 1pm sandwich. These patterns existed before the CGM; patients simply couldn’t see them.

The early warning sign most articles miss: alert fatigue. Patients who set their CGM alarms too aggressively—alerts for any glucose above 140 or below 100—develop decision fatigue within weeks. They stop responding to alerts because the signal-to-noise ratio is terrible. This isn’t laziness; it’s cognitive overload. Effective CGM use requires calibrating alerts to meaningful thresholds, not every minor fluctuation.

Other commonly overlooked experiences include phantom notifications (anxiety about upcoming alerts even when they’re not sounding), social discomfort from visible sensors during intimate moments, and “CGM creep”—obsessively checking readings dozens of times daily, which impairs rather than improves control.

How Diagnosis Actually Works: Testing and Criteria

Here’s where most articles confuse things. A CGM doesn’t diagnose diabetes. Diabetes diagnosis requires fasting glucose ≥126 mg/dL, 2-hour glucose ≥200 mg/dL on oral glucose tolerance test, or HbA1c ≥6.5%, per American Diabetes Association criteria.

CGM prescription happens after diagnosis. Your doctor orders a CGM when finger-stick data or HbA1c suggests poor control, or when you’re at risk for hypoglycemia unawareness. Insurance typically covers CGM for Type 1 diabetes automatically, but Type 2 coverage requires documented poor control (HbA1c >7-8.5% depending on the insurer).

The real process involves insertion by a medical assistant—a 1-2 minute procedure creating minimal discomfort, similar to getting an IV. Some systems (Dexcom, Freestyle Libre 2) transmit via Bluetooth to your phone; others require scanning. Most require 2-hour warm-up before functioning. The first week is diagnostic—you’re learning your patterns, not yet optimizing. Real behavior change starts week two.

Treatment Options: What Works and Why Selection Matters

CGM doesn’t treat diabetes directly; it informs treatment. But the CGM system you choose shapes which treatment options become visible and feasible.

Dexcom G7 transmits automatically to your phone and smartwatch every 5 minutes, making it ideal for insulin pump users and those who benefit from frequent trend arrows. The system shows directional arrows indicating whether glucose is rising or falling rapidly—crucial for preventing hypoglycemia.

Freestyle Libre 2 requires scanning (or Bluetooth scanning if you use the reader), creating a moment of intentionality—you actively choose to check rather than passively receiving alerts. This suits some patients; others find it discouraging when they avoid scanning knowing the number is bad.

Medtronic Guardian 4 integrates with their 780G insulin pump, which automatically adjusts basal insulin delivery based on CGM readings. This hybrid closed-loop system significantly reduces nighttime hypoglycemia and HbA1c.

The treatment decision tree: Are you on insulin? Then Dexcom or Guardian 4 makes most sense. Are you on oral medications or GLP-1 agonists like semaglutide? Freestyle Libre 2 typically suffices, though some benefit from Dexcom’s alerts. Do you struggle with hypoglycemia unawareness? You need audible alerts and predictive alarms—Dexcom’s “high glucose” and “low glucose” projections 15-20 minutes ahead are valuable here.

Practical Daily Management: Concrete Strategies That Work

Here’s what separates effective CGM users from those who abandon the technology within months.

Set smart alert thresholds: Don’t alert for every glucose above 140. Instead, set low threshold at 70 mg/dL and high threshold at 180-200 mg/dL initially. Gradually tighten as you learn your patterns. Range alerts exist to guide you toward your target range, not to bombard you with data.

Review trends during specific meals: Pick one meal daily—breakfast, lunch, or dinner—and actively observe your glucose response. Document what you eat, when you eat it, portion size, and the glucose pattern that follows. After 2-3 weeks, patterns emerge. Your body might handle carbs differently at different times.

Identify your “glucose lag”: Eat a consistent meal (same carbs, same amount) and note when glucose begins rising. Most patients see a rise 10-20 minutes after starting to eat. This lag determines when to take rapid-acting insulin.

Use the direction arrow to predict lows: When your glucose is 120 and dropping sharply, consuming 15 grams of carbs now prevents the 65 mg/dL low that would occur without intervention. Finger-stick testing can’t predict; CGM trends can.

Account for exercise timing: Many patients expect glucose to drop during exercise, then are surprised when it rises 30-60 minutes later (hepatic glucose output). CGMs reveal these delayed patterns that single measurements never would.

Prevention: Evidence and Caveats

This section needs honesty: CGMs don’t prevent diabetes. They don’t prevent complications. They improve outcomes if you respond to the data they provide.

The evidence shows CGM use correlates with improved HbA1c and reduced hypoglycemia, but correlation requires causation through behavior change. A study published by NIH showed that patients who review their CGM data weekly with a provider reduce HbA1c more than those receiving the device without coaching. The device itself is inert; your response determines everything.

Preventing complications (retinopathy, nephropathy, neuropathy) requires maintaining glucose time-in-range: roughly 70% of time spent between 70-180 mg/dL for most patients. CGM enables tracking time-in-range precisely. But achieving it requires dietary adjustment, medication optimization, and sometimes insulin initiation—actions that CGM merely informs.

<p